Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses

Topic: Drug trials: efficacy and safety

Glutamate is the major excitatory neurotransmitter in the brain. The NMDA subtype of glutamate receptors (NMDAR) is known to mediate many physiological neural functions. However, excessive activation of NMDARs contributes to neuronal damage in various acute and chronic neurological disorders. To avoid unwanted adverse side effects, blockade of excessive NMDAR activity must therefore be achieved without affecting its physiological function. Memantine, an adamantane derivative, has been used for the treatment of Alzheimer's disease with an excellent clinical safety profile. We previously showed that memantine preferentially blocked neurotoxicity mediated by excessive NMDAR activity while relatively sparing normal neurotransmission, in part because of its uncompetitive antagonism with a fast off-rate. Here, using rat autaptic hippocampal microcultures, we show that memantine at therapeutic concentrations (1-10 microM) preferentially blocks extrasynaptic rather than synaptic currents mediated by NMDARs in the same neuron. We found that memantine blocks extrasynaptic NMDAR-mediated currents induced by bath application of 100 microM NMDA/10 microM glycine with a twofold higher potency than its blockade of the NMDAR component of evoked EPSCs (EPSCs(NMDAR)); this effect persists under conditions of pathological depolarization in the presence of 1 mm extracellular Mg(2+). Thus, our findings provide the first unequivocal evidence to explain the tolerability of memantine based on differential extrasynaptic/synaptic receptor blockade. At therapeutic concentrations, memantine effectively blocks excessive extrasynaptic NMDAR-mediated currents, while relatively sparing normal synaptic activity.

Key findings

• We previously showed that memantine preferentially blocked neurotoxicity mediated by excessive NMDAR activity while relatively sparing normal neurotransmission, in part because of its uncompetitive antagonism with a fast off-rate.
• We found that memantine blocks extrasynaptic NMDAR-mediated currents induced by bath application of 100 microM NMDA/10 microM glycine with a twofold higher potency than its blockade of the NMDAR component of evoked EPSCs (EPSCs(NMDAR)); this effect persists under conditions of pathological depolarization in the presence of 1 mm extracellular Mg(2+).
• Thus, our findings provide the first unequivocal evidence to explain the tolerability of memantine based on differential extrasynaptic/synaptic receptor blockade.

New to this subject? Start with our plain-English guide: Treatments →

Study details

• Evidence strengthLow

Read the original

• DOI: 10.1523/jneurosci.2488-10.2010
• PubMed: 20720132
• Original source →

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

@article{xia2010-20720132,
  author  = {Xia, P. and Chen, H. S. and Zhang, D. and Lipton, S. A.},
  title   = {{Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses}},
  journal = {The Journal of neuroscience : the official journal of the Society for Neuroscience},
  year    = {2010},
  doi     = {10.1523/jneurosci.2488-10.2010},
  pmid    = {20720132},
  url     = {https://doi.org/10.1523/jneurosci.2488-10.2010}
}

Related studies in Treatments

• Amyloid-beta peptide oligomers disrupt axonal transport through an NMDA receptor-dependent mechanism that is mediated by glycogen synthase kinase 3beta in primary cultured hippocampal neurons The Journal of neuroscience : the official journal of the Society for Neuroscience · 2010-07-01 · usefulness score 36/100
• Mechanism of NMDA receptor channel block by MK-801 and memantine Nature · 2018-04-18 · usefulness score 43/100
• Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond Nature reviews. Drug discovery · 2006-02-01 · usefulness score 36/100
• Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse Neuropharmacology · 2007-08-10 · usefulness score 36/100
• N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease Current Alzheimer research · 2012-07-01 · usefulness score 36/100
• The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence International journal of geriatric psychiatry · 2003-09-01 · usefulness score 36/100

Similar studies

• The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism 2005 · Treatments
• Memantine for the Treatment of Dementia: A Review on its Current and Future Applications 2018 · Treatments
• The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease 2003 · Treatments
• Mg2+ imparts NMDA receptor subtype selectivity to the Alzheimer's drug memantine 2009 · Treatments
• Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1-40) 2002 · Biomarkers
• Mechanism of action of memantine 2006 · Treatments

More on Treatments

• A review that covers this ground AChE Inhibitors and NMDA Receptor Antagonists in Advanced Alzheimer's Disease The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists · 2017-09-01 · usefulness score 68/100
• Newest in this subject Opposing Regulation of Tau Condensation by Phosphorylation Levels and Molecular Chaperone Interactions bioRxiv · 2026-10-30 · Preprint — not yet peer-reviewed · usefulness score 16/100
• Newest in this subject Natural Sesquiterpenoids from Laggera pterodonta as bioactive Acetylcholinesterase Inhibitors: Insights from DFT, Molecular Docking, and ADMET Profiling Research Square · 2026-10-20 · Preprint — not yet peer-reviewed · usefulness score 16/100

See all studies in Treatments →